(Bloomberg)--Bristol-Myers Squibb Co.’s immune cancer therapywon approval from U.S. regulators for a broader population of lungcancer patients, a boost for a drug that’s expected to become ablockbuster.

The decision by the Food and Drug Administration camealmost three months ahead of schedule, following a trend of quickerclearances for new cancer drugs by the agency.

In March, Opdivo was approved three months ahead of planfor use in patients with advanced squamous, non-small cell lungcancer whose disease had progressed during or after tryingchemotherapy.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.